- The Lancet medical journal reported that the Russian coronavirus vaccine tested positive in the first trial
- The vaccine induced antibodies in all participants and showed an aid to the immune system to fight the infection
- “We are convinced that we have the best vaccine in the world,” said the executive director of the Russian Fund for Direct Investment.
According to the British medical journal Lancet, the Russian vaccine against COVID-19 showed an antibody response in all participants in the first trial and there were no serious adverse effects, as reported Bloomberg.
Also, the vaccine caused a response in T cells, a kind of white blood cell that helps the immune system to fight the virus infection.
The results of the phase 1 and 2 trials were published this Friday in The Lancet, however, Russian officials had offered similar information regarding the effectiveness of the Russian vaccine without having been verified by external experts.
On Tuesday, August 11, Russian President Vladimir Putin stressed that the vaccine had passed the necessary tests, and mentioned that one of his two daughters had received an injection and was feeling fine, AP detailed.
“I would like to repeat that it has passed all the necessary tests. The most important thing is to ensure the total safety of using the vaccine and its efficacy, ”he emphasized at the time.
At the time, many scientists within and outside the country were skeptical, questioning the decision to register the vaccine before phase 3 trials, which typically last months and involve thousands of people.
Kirill Dmitriev, executive director of the Russian Fund for Direct Investment, which has supported the Russian vaccine since the beginning, said the Lancet report marks a “turning point” after the “attacks” on the project.
“Russia has responded to the questions that have been asked about it,” he said in a conference call. “And we are convinced that we have the best vaccine in the world,” he said.
The trials of the Russian vaccine were carried out in two hospitals in the country and involved 76 healthy adults between 18 and 60 years of age. All participants received the vaccine and there was no placebo group.
“We plan to produce 30 million doses of this vaccine in Russia during the current year,” he said. Dmitriev in August.
The government announced that the first to receive the Russian vaccine would be teachers and medical personnel, and a much larger national vaccination campaign would be launched by the end of the year.
On August 26, a phase 3 trial was approved for 40,000 volunteers of different ages and risk groups.
“Immunogenicity bodes well, although nothing can be inferred about immunogenicity in older age groups, and the clinical efficacy of any Covid-19 vaccine has not yet been demonstrated,” said Naor Bar-Zeev, associate professor of the Johns Hopkins Bloomberg School of Public Health, in a linked comment in The Lancet.
“Showing safety will be crucial with Covid-19 vaccines, not only for vaccine acceptance, but also for confidence in vaccination in general,” he said.
Mexico seeks to participate in Russian vaccine trials against COVID-19 in October
Mexico seeks to participate in phase 3 of the Russian vaccine against COVID-19 in October, if it is approved by the Ministry of Health and the Federal Commission for the Protection against Sanitary Risks (Cofepris), Foreign Minister Marcelo Ebrard reported this Thursday.
“In the first days of October, if the regulatory authority considers it so, hopefully so, that vaccine can be brought to Mexico,” said Ebrard at a conference in the framework of the presentation of results of the Mexican Foundation for Health (Funsalud), according to the Efe agency.
He pointed out that the idea is to “enroll volunteers in Mexico, develop a protocol of several thousand and, in short, test that vaccine in our country in a period as close as next month.”
The chancellor is the one who heads the negotiations of the Mexican Government with different companies and governments of the world to participate in different investigations that seek a vaccine against the coronavirus.
A few weeks ago, the Government of President Andrés Manuel López Obrador announced an agreement with the firm AstraZeneca, the University of Oxford, the Carlos Slim Foundation and the Government of Argentina to produce the vaccine from November and that it be distributed in the first months of 2021.
At the virtual conference, in which Tagir Sitdekov, representative of the Russian Direct Investment Fund (RDIF), the Russian fund that supports the Sputnik V investigation, participated, Ebrard explained that the Russian Government will send the results of the phase 1 and 2 of clinical trials.
These will be delivered to the authorities of the Ministry of Health and the regulatory authority, Cofepris, next week.
“If the results are positive, and that the regulatory authority that I already mentioned, Cofepris, so decides, then it will be available in the coming months in Mexico,” said Ebrard, who estimated that between 500 and 1,000 Mexicans could participate in the study. , between 18 and 60 years old.
The Mexican Foreign Minister recalled that the representative of the Russian fund “is looking for travel companions for what is to come next, which is production, as was done with AstraZeneca, and it will surely happen with other (investigations)”
He stressed that Mexico participates in as many protocols as possible in order to guarantee access to vaccines and learn what each of these vaccines are like and so that Mexico arrives on time.
Until this Wednesday, the Ministry of Health of Mexico reported 610,957 cases and 65,816 deaths accumulated by COVID-19, with an increase in the last 24 hours of 4,921 infections and 525 deaths.
The post Russian coronavirus vaccine tests positive, report appeared first on Hispanic World.